⌘K
Loading ticker…
As of 2026-08-24, Novavax Inc (NVAX) has a 3-month relative strength percentile of 40 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 52. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 4.7%, relative volume 1.38×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
NVAX is in a stage 3 topping pattern, week 3. Currently in a 123-day base; basing ADR 5.7% (broad 5.2%). VCP detected: 3 contractions. RS line below base-start high. Distance from 50d / 200d: 4.8% / 4.9%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
NVAX is held by 22 ETFs as of May 2026. Top owner: SCHA at 0.04% weight, $9M notional. Top 3 carry $22M.
Held by 56 ETFs · $243M across latest filings · largest weight 1.93% (BBP).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| SCHASchwab U.S. Small-Cap ETF | 0.04% | $9M | — |
| VTWO | 0.05% | $8M | — |
| VHTVanguard Health Care ETF | 0.02% | $5M | — |
| SBIO | 1.14% | $2M | +0.07 pp |
| VTWG | 0.08% | $1M | — |
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 0.00% |
| $1M |
| — |
| ONEQ | 0.01% | $586K | new |
| BFOR | 0.25% | $528K | new |
| VTWV | 0.02% | $223K | — |
| VTHRVanguard Russell 3000 ETF | 0.00% | $136K | — |
Showing 10 of 22 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NVAX Jan avg: 7.29% median: 7.11% win: 75% σ: 19.73% n: 4 2022-04-12 → 2026-07-31 | NVAX Feb avg: 4.72% median: 5.25% win: 50% σ: 17.54% n: 4 2022-04-12 → 2026-07-31 | NVAX Mar avg: -17.79% median: -21.39% win: 0% σ: 9.96% n: 4 2022-04-12 → 2026-07-31 | NVAX Apr avg: -3.80% median: -2.64% win: 40% σ: 12.49% n: 5 2022-04-12 → 2026-07-31 | NVAX May avg: 64.66% median: 22.77% win: 100% σ: 102.81% n: 5 2022-04-12 → 2026-07-31 | NVAX Jun avg: -11.76% median: -14.13% win: 0% σ: 4.07% n: 5 2022-04-12 → 2026-07-31 | NVAX Jul avg: 3.07% median: 5.56% win: 80% σ: 16.87% n: 5 2022-04-12 → 2026-07-31 | NVAX Aug avg: -11.05% median: -8.58% win: 25% σ: 21.73% n: 4 2022-04-12 → 2026-07-31 (current) | NVAX Sep avg: -9.08% median: -3.74% win: 50% σ: 26.07% n: 4 2022-04-12 → 2026-07-31 | NVAX Oct avg: -3.17% median: -5.56% win: 25% σ: 19.20% n: 4 2022-04-12 → 2026-07-31 | NVAX Nov avg: -17.18% median: -16.74% win: 0% σ: 6.86% n: 4 2022-04-12 → 2026-07-31 | NVAX Dec avg: -15.72% median: -10.26% win: 0% σ: 15.00% n: 4 2022-04-12 → 2026-07-31 |